ATE278019T1 - Neuartige rezeptor-typ tyrosinkinase und deren verwendung - Google Patents

Neuartige rezeptor-typ tyrosinkinase und deren verwendung

Info

Publication number
ATE278019T1
ATE278019T1 AT92913639T AT92913639T ATE278019T1 AT E278019 T1 ATE278019 T1 AT E278019T1 AT 92913639 T AT92913639 T AT 92913639T AT 92913639 T AT92913639 T AT 92913639T AT E278019 T1 ATE278019 T1 AT E278019T1
Authority
AT
Austria
Prior art keywords
type tyrosine
tyrosine kinase
receptor type
novel receptor
receptor
Prior art date
Application number
AT92913639T
Other languages
English (en)
Inventor
Andrew D Boyd
Richard Simpson
Ian Wicks
Larry David Ward
David Wilkinson
Original Assignee
Inst Medical W & E Hall
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Medical W & E Hall filed Critical Inst Medical W & E Hall
Application granted granted Critical
Publication of ATE278019T1 publication Critical patent/ATE278019T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT92913639T 1991-06-21 1992-06-19 Neuartige rezeptor-typ tyrosinkinase und deren verwendung ATE278019T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPK684191 1991-06-21
AUPK999291 1991-12-12
PCT/AU1992/000294 WO1993000425A1 (en) 1991-06-21 1992-06-19 A novel receptor-type tyrosine kinase and use thereof

Publications (1)

Publication Number Publication Date
ATE278019T1 true ATE278019T1 (de) 2004-10-15

Family

ID=25644064

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92913639T ATE278019T1 (de) 1991-06-21 1992-06-19 Neuartige rezeptor-typ tyrosinkinase und deren verwendung

Country Status (10)

Country Link
US (3) US5674691A (de)
EP (1) EP0590030B1 (de)
JP (2) JP3955316B2 (de)
AT (1) ATE278019T1 (de)
AU (1) AU655299B2 (de)
CA (1) CA2111006C (de)
DE (1) DE69233421T2 (de)
ES (1) ES2230537T3 (de)
NZ (1) NZ243252A (de)
WO (1) WO1993000425A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE278019T1 (de) * 1991-06-21 2004-10-15 Inst Medical W & E Hall Neuartige rezeptor-typ tyrosinkinase und deren verwendung
PT669929E (pt) * 1992-11-13 2007-04-30 Immunex Corp Ligando de elk, uma citoquina
US5516658A (en) 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
US6001621A (en) * 1993-11-23 1999-12-14 Genetech, Inc. Protein tyrosine kinases
CA2175893C (en) 1993-11-23 2010-06-22 Paul J. Godowski Protein tyrosine kinases named rse
EP0756627A1 (de) * 1994-04-15 1997-02-05 Amgen Inc. Hek5, hek7, hek8, hek11, neue eph-ähnliche tyrosinkinase-rezeptoren
US6992175B1 (en) 1994-04-15 2006-01-31 Amgen Inc. Nucleic acids encoding Eph-like receptor tyrosine kinases
CA2122874A1 (en) * 1994-04-29 1995-10-30 Anthony Pawson Neural receptor tyrosine kinase
US5585269A (en) * 1994-06-02 1996-12-17 The University Of North Carolina At Chapel Hill Isolated DNA encoding c-mer protooncogene
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5795734A (en) * 1994-09-19 1998-08-18 President And Fellows Of Harvard College EPH receptor ligands, and uses related thereto
US6300482B1 (en) * 1995-01-03 2001-10-09 Max-Flanck-Gesellschaft Zuer For{Overscore (D)}Erung Der MDKI, a novel receptor tyrosine kinase
US6057124A (en) * 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
WO1997014966A1 (en) * 1995-10-13 1997-04-24 Mount Sinai Hospital Corporation Method of activating a novel ligand regulatory pathway
CA2259157A1 (en) * 1996-07-05 1998-01-15 Mount Sinai Hospital Corporation Oligomerized receptors which affect pathways regulated by transmembrane ligands for elk-related receptor tyrosine kinases
AUPO754997A0 (en) 1997-06-25 1997-07-17 Leukaemia Foundation Of Queensland, The Receptor-ligand system and assay therefor
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US7625859B1 (en) * 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7396810B1 (en) * 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US20020034740A1 (en) * 1999-01-21 2002-03-21 Patricia A. Billing-Medel Reagents and methods useful for detecting diseases of the breast
WO2000050589A1 (en) * 1999-02-22 2000-08-31 Ludwig Institute For Cancer Research TYROSINE KINASE RECEPTOR EphA3 ANTIGENIC PEPTIDES
US7192698B1 (en) 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US6852510B2 (en) 2000-07-03 2005-02-08 Gala Design Inc Host cells containing multiple integrating vectors
US20030224415A1 (en) * 2001-06-29 2003-12-04 Gala Design, Inc. Selection free growth of host cells containing multiple integrating vectors
AU2001270252B2 (en) * 2000-07-03 2007-02-08 Catalent Pharma Solutions, Llc Expression vectors
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
US20030148394A1 (en) * 2002-01-18 2003-08-07 Millennium Pharmaceuticals, Inc. Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058, or 6351 molecules
US7384738B2 (en) * 2002-03-28 2008-06-10 Bremel Robert D Retrovirus-based genomic screening
US20040038304A1 (en) * 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
EP1605961A4 (de) 2003-03-12 2009-11-11 Vasgene Therapeutics Inc Polypeptid-verbindungen zur hemmung der angiogenese und des tumorwachstums
US20050239088A1 (en) * 2003-05-16 2005-10-27 Shepard H M Intron fusion proteins, and methods of identifying and using same
US20050221429A1 (en) * 2004-01-16 2005-10-06 Cardinal Health Pts, Llc Host cells containing multiple integrating vectors comprising an amplifiable marker
WO2005090406A2 (en) 2004-03-12 2005-09-29 Vasgene Therapeutics, Inc. Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
KR20120123619A (ko) 2004-03-12 2012-11-08 바스진 테라퓨틱스, 인크. 혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물
EP1745073A2 (de) * 2004-05-14 2007-01-24 Receptor Biologix, Inc. Isoformen eines zelloberflächenrezeptors und verfahren zu deren identifizierung und anwendung
US20080199480A1 (en) * 2004-07-22 2008-08-21 Sequenom, Inc. Methods for Identifying Risk of Type II Diabetes and Treatments Thereof
WO2006034455A2 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
WO2006042002A2 (en) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
WO2006071451A2 (en) * 2004-12-03 2006-07-06 The Regents Of The University Of California Compounds that prevent macrophage apoptosis and uses thereof
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
EP3199180B1 (de) 2007-03-08 2022-01-05 Humanigen, Inc. Ep ha3-antikörper zur behandlung von soliden tumoren
CN102083861B (zh) 2007-08-13 2016-04-13 瓦斯基因治疗公司 使用结合EphB4的人源化抗体的癌症治疗
US8834870B2 (en) 2009-03-06 2014-09-16 Kalobios Pharmaceuticals, Inc. Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3
AU2010313621C1 (en) 2009-10-14 2015-11-26 Humanigen, Inc. Antibodies to EphA3

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693778A (en) * 1987-12-21 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Arg a human gene related to but distinct from abl proto-oncogene
WO1991005288A1 (en) * 1989-10-05 1991-04-18 Eastman Kodak Company Camera apparatus for magnetically recording on film
ATE278019T1 (de) * 1991-06-21 2004-10-15 Inst Medical W & E Hall Neuartige rezeptor-typ tyrosinkinase und deren verwendung
AU4651893A (en) * 1992-06-26 1994-01-24 Immunex Corporation Novel tyrosine kinase
PT669929E (pt) * 1992-11-13 2007-04-30 Immunex Corp Ligando de elk, uma citoquina
US5457048A (en) * 1993-12-03 1995-10-10 La Jolla Cancer Research Foundation Eph-related tyrosine kinases, nucleotide sequences and methods of use

Also Published As

Publication number Publication date
US6599709B1 (en) 2003-07-29
JP4330594B2 (ja) 2009-09-16
CA2111006C (en) 2008-04-08
JP2006187296A (ja) 2006-07-20
US6020306A (en) 2000-02-01
EP0590030B1 (de) 2004-09-29
ES2230537T3 (es) 2005-05-01
NZ243252A (en) 1995-11-27
AU655299B2 (en) 1994-12-15
AU2163592A (en) 1993-01-25
CA2111006A1 (en) 1993-01-07
EP0590030A1 (de) 1994-04-06
DE69233421T2 (de) 2006-02-23
DE69233421D1 (de) 2004-11-04
JPH06508747A (ja) 1994-10-06
WO1993000425A1 (en) 1993-01-07
US5674691A (en) 1997-10-07
EP0590030A4 (en) 1997-04-23
JP3955316B2 (ja) 2007-08-08

Similar Documents

Publication Publication Date Title
DE69233421D1 (de) Neuartige rezeptor-typ tyrosinkinase und deren verwendung
Imhof et al. Cell-cell interaction and polarity of epithelial cells: specific perturbation using a monoclonal antibody
ATE440868T1 (de) Monoklonaler antikírper gegen ein prion protein und dessen verwendung zum nachweis von prionen
UA27763C2 (uk) Рекомбінантна молекула днк, що кодує молекулу адгезії icam-3, молекула адгезії icam-3, антитіло, здатне зв'язуватись з такою молекулою, фармацевтична композиція
GR3036906T3 (en) Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof.
IL100343A0 (en) G protein coupled glutamate receptors
ATE324441T1 (de) Htk-ligand
NO891375D0 (no) Nye polypeptider med vekstfaktoraktivitet og nukleinsyresekvenser som koder for polypeptidene.
DK1129186T3 (da) Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
ES8900246A1 (es) Un procedimiento para la preparacion de anticuerpos especificos para uno de los miembros de la familia p 2 de proteinas
EP0628054A4 (de) Car-rezeptoren und verwandte moleküle und entsprechende methoden.
DK0759942T3 (da) Interleukin-15-receptorer
KR920018078A (ko) neu수용체 자극 인자 및 그의 제조방법과 그를 이용하여 세포의 증식 및 분화를 조절하는 방법
FI925321A0 (fi) Immunodiagnostiskt ledinflammationstest
ATE331732T1 (de) Schaumproteine, monoklonale antikörper dagegen, und deren verwendungen
EP0804576A4 (de) Hemopoietin-Rezeptor
ES2109225T3 (es) Anticuerpos, su produccion y uso.
WO1996023884A3 (en) Human peroxisome proliferator activated receptors
DE3851226D1 (de) Wachstumsfaktor-rezeptor.
ATE103973T1 (de) Gamma-atriales, natriuretisches polypeptid erkennende monoklonale antikoerper, solche antikoerper produzierende hybridome und deren herstellung und verwendung.
ATE317851T1 (de) Polypeptide mit aminosäuresequenzen aus dem n- terminalen bereich von gp116 von cytomegalovirus und deren verwendung bei der diagnostik, prophylaxe und therapie
BIRCHMEIER Microfilaments and Fibronectin Fibers Involved in the Formation of Fibroblast'S Focal Contacts
Kim et al. Production rind Characterization of the Polyclonal Anti-peptide Antibody for $ eta $-adrenergic Receptor
Meager RIA, IRMA, and ELISA for cytokines and their soluble
ATE239754T1 (de) An nukleinsäure gebundenes polypeptid, verfahren zur herstellung eines an nukleinsäure gebundenen polypeptides und immunoassay, in dem dieses polypeptid verwendung findet

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties